Under the Microscope: Why India’s Drug Regulator Is Targeting Small Pharma Firms

ndia’s regulatory spotlight is shifting. The Drugs Controller General of India (DCGI) has recently launched an aggressive crackdown on small- and medium-sized pharmaceutical manufacturers—particularly those in […]

November 14, 2025

Published by team_admin at November 14, 2025

Redrawing the Patent Map: How India’s Crackdown on “Evergreening” is Rewriting Pharma IP Strategy

When the Patents Act, 1970’s Section 3(d) came into sharper focus through the Novartis AG v. Union of India ruling and subsequent cases, it marked more […]

November 11, 2025

Published by team_admin at November 11, 2025

Pharma’s New Gold Rush: Inside the Explosive Race for Next-Gen Weight-Loss Drugs

In a world where body weight often dictates health outcomes, the race to develop effective weight-loss medications has morphed into one of the most fiercely contested […]